EUCTR2009-018146-38-FR进行中（未招募）不适用
Multicenter randomized controlled study comparing the efficacy and safety of natural Multi-subtype interferon alpha (Multiferon) in association with ribavirin versus retreatment with pegylated interferon-alpha 2a and ribavirin in non-responding genotype 1 hepatitis C patients. - Must Have
Swedish Orphan International AB0 个研究点目标入组 250 人开始时间: 2010年3月16日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 250
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Male or female between 18 and 65 years of age
- •2.Patient with documented genotype 1 chronic hepatitis C infection with detectable HCV RNA (> 25 IU/mL) in serum
- •3.Previous non response to peg-interferon plus ribavirin treatment, defined as patients with documented response of at least a 1 log decrease of their viral load at week 12 to a prior course of SOC who did not achieve undetectable HCV-RNA at the end of treatment. Can be included both:
- •3.1.Patient who had an undetectable HCV RNA level during prior course of Peg-IFN/ribavirin therapy but regained detectable HCV RNA before therapy ended (breakthrough patients);
- •3.2. Patients presenting, after 12 weeks of treatment with a viral decrease less than 2 log
- •3.3.Patients who did not achieve a negative viral load after 24 weeks of given treatment
- •4.Well-documented previous SOC treatment with peg-interferon and ribavirin with HCV RNA levels measured at baseline, at week 12, and at the end of the treatment period.
- •5.Patients who showed a compliance to previous treatment with peg-interferon and ribavirin of at least 80%
- •6.Patient has had a liver biopsy and/or Fibroscan evaluation within 1 year prior to study inclusion showing a metavir score of F3 or less or less than 10 kPA.
- •7.Screening laboratory values of the following variables must meet the acceptable values defined below: Laboratory Variable Acceptable Range
- •Absolute neutrophil count = 1500/mm3
- •Platelet count = 100000/mm3
- •Haemoglobin = 12 g/dL for females = 13 g/dL for males
- •Creatinine clearance > 50 ml/min
- •Uric acid within normal range
- •All other hematology and clinical chemistry results (except for transaminases) within normal limits or showing no clinically significant abnormalities
- •8.All fertile males must accept effective contraception for both themselves and their partners during treatment and during 7 months after the treatment ends and for the female partners to undergo pregnancy tests monthly during the same period. .
- •9. All fertile females must accept effective contraception for both themselves and their partner during treatment and during 4 months after the treatment ends and to undergo pregnancy tests monthly during the same period.
- •10.Patient is able to read and understand, and is willing to sign the Informed Consent Form (ICF) voluntarily before first trial-related activity
- •11.Patient agrees to not participate in other clinical trials
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Patients having an hypersensitivity to interferon-alpha or ribavirin or any of the excipients used in Multiferon, Copegus or Pegasys
- •2.Patient having intolerance or side effects during previous peg-interferon plus ribavirin treatment leading to discontinuation of at least one of the two drugs
- •3.Women who are pregnant, planning to become pregnant, or breastfeeding, and males whose partner plans to become pregnant
- •4.Patients having been treated by immunosuppressive agents within 6 months
- •5.Patients having received HCV antiviral drugs or any investigational drug within 12 weeks prior to study inclusion
- •6.Patient having an history of organ transplants that requires chronic immunosuppression
- •7.Epilepsy if not well controlled by conventional medication
- •8.Patients co-infected with HIV and/or hepatitis B
- •9.Suspicion of alcohol, barbiturate, or amphetamine recreational or of narcotic drug use, which in the investigator’s opinion would compromise the subject’s safety and/or compliance with study procedures
- •10.Patient has a concomitant medical condition that in the opinion of the investigator could influence the results of the trial or that could represent an additional risk for the administration of the study drugs to the subject
- •11.Patient has medical contraindication to the administration of Peg-IFN alfa-2a or ribavirin, including, but not limited to:
- •?abnormal thyroid function not controlled effectively with conventional treatment;
- •?history of clinically significant pre-existing cardiac disease, including unstable or uncontrolled cardiac disease, in the previous 6 months
- •?evidence of autoimmune disease;
- •?history of hemoglobinopathies(e.g. thalassemia, sickle-cell anaemia).
- •12.Pre-existing psychiatric condition that could interfere with the patient’s participation and completion of the study, including but not limited to:
- •?severe depression or hospitalization for depression;
- •?history of severe depression during the previous treatment with pegIFN and ribavirin
- •?schizophrenia, bipolar illness, severe anxiety or personality disorder;
- •?a period of disability or impairment due to a psychiatric disease within the past 5 years.
- •13.Subject has history of decompensated liver disease: history of ascites,hepatic encephalopathy, or bleeding esophageal varices, and/or any of the following screening laboratory results:
- •?International Normalized Ratio (INR) of = 1.5;
- •?Serum albumin < 3.3 g/dL;
- •?Serum total bilirubin > 1.8 times the upper limit of normal (ULN), unless isolated and for subjects with Gilbert’s Syndrome.
- •14.Any evidence of significant liver disease in addition to hepatitis C, which may include, but is not limited to, hepatitis B virus (HBV) infection, drug or alcohol-related cirrhosis, autoimmune hepatitis, hemochromatosis, Wilson’s disease, or primary biliary cirrhosis.
研究者
相似试验
招募中
1 期
Randomized controlled multicenter study comparing efficacy and safety of adalimumab to that of mycophenolate mofetil in steroid dependent non-infectious uveitis” - FOCUSrecently active non-infectious intermediate, posterior, and pan-uveitisMedDRA version: 20.0Level: PTClassification code: 10046851Term: Uveitis Class: 100000004853CTIS2023-505112-38-00Assistance Publique Hopitaux De Paris120
已完成
不适用
Carvedilol tablets compared with endoscopic banding treatment in preventing rebleeding from oesophgaeal varicesVariceal rebleeding in cirrhotic patientsDigestive SystemOther diseases of liverISRCTN69643049Greater Glasgow & Clyde (UK)152
已完成
不适用
A multicenter randomized controlled study comparing needles with and without side hole for EUS guided fine needle biopsy in diagnosis of pancreatic solid lesions.Pancreatic tumorsJPRN-UMIN000010021Osaka EUS-FNA Study Group200
进行中（未招募）
不适用
Multicenter randomized controlled trial comparing intravenous iron infusion with oral iron suppletion in the preoperative work-up of patients with anemia that undergo surgery for cancer in the bowel.Patients with anemia that undergo curative surgery in case of a colorectal carcinomaEUCTR2014-002827-87-NLAcademic Medical Center
尚未招募
不适用
Multicenter randomized controlled trial comparing intensive nutritional support versus conventional nutritional support for gastric cancer patients who underwent gastric resection.NeoplasmsKCT0003717Seoul National University Bundang Hospital80